A 'big data' approach to developing cancer drugs

July 7, 2016, Cell Press
This visual abstract captures how a look at the pharmacogenomics landscape of 1,001 human cancer cells lines points to new treatment applications for hundreds of known anti-cancer drugs. Credit: Iorio et al./Cell 2016

Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study publishing July 7 in Cell, researchers compared genetic mutations in patient tumors to those in cancer cell lines and then tested the cell lines' responses to therapeutic compounds. By analyzing where these datasets overlap, researchers can begin to predict on a large scale which drugs will best fight various cancers.

"The process that we've done, by nature, is a discovery process," says Mathew Garnett, a cancer biologist at the Wellcome Trust Sanger Institute. "It's the beginning of generating exciting new ideas about how we might target specific patient populations with specific drugs. This type of study wasn't possible a few years ago because we hadn't sequenced enough patient tumors."

When developing new anti-cancer drugs, researchers often rely first on cancer cell lines in the lab. "You can't screen hundreds of drugs across a single patient. It's not possible," says Ultan McDermott, a cancer clinician and researcher also at the Sanger Institute. "But you can do that with cell lines—you can expose them to many different drugs and ask questions about which is more or less sensitive."

How closely these cell lines match what actually happens in a human tumor has been unclear, however, and previous efforts to model drug response using cancer cell lines were done on a relatively small scale. To investigate a larger piece of the landscape, Garnett, McDermott, and their colleagues analyzed data from two public datasets, The Cancer Genome Atlas and the International Cancer Genome Consortium, and other studies, gathering genetic information for more than 11,000 tumor samples.

The team then compared these tumor samples to about 1,000 cancer cell lines used in labs, looking for lines that had the same types of mutations as the patient samples—and therefore might more closely mimic patient responses. "Many of the cell lines do capture the molecular features that are important to human beings in cancer," says McDermott.

Once they mapped the tumor mutations onto the cell lines, the researchers looked for the genetic mutations that could best predict the cancer cells' response to 265 different anti-cancer compounds at various stages of development. The drugs covered a range of mechanisms, including chemotherapeutics, small-molecule inhibitors, epigenetic modulators, and cell death regulators.

Many of the mutations that occurred both in tumor samples and cell lines did signal whether the cancer cells would be sensitive or resistant to different compounds, largely depending on the type of tissue the cancer originated in. "If you can identify the clinically relevant features in cell lines and correlate those with drug response, you're one step closer to identifying a drug interaction that could be important for a patient," says McDermott.

"We've taken a leap forward in doing this type of study in a very comprehensive and systematic way, as opposed to what often is done, where someone might do it with a single drug or in a single cell line," explains Garnett. "It's by no means the end of the journey—but it's a huge milestone."

Going forward, the researchers are creating a web portal to share their data, which will allow cancer researchers to see which cell lines most closely mirror the patient condition they aim to emulate and how those cell lines respond to different drugs. Garnett and McDermott's teams are also starting their own follow-up projects to investigate associations between certain cell mutations and drug effects, with the hope of more clearly pinpointing which cancer patients will most benefit from a given compound.

Explore further: Patient cancer cells help to test treatments

More information: Cell, Iorio et al.: "A landscape of pharmacogenomic interactions in cancer" www.cell.com/cell/fulltext/S0092-8674(16)30746-2 , DOI: 10.1016/j.cell.2016.06.017

Related Stories

Patient cancer cells help to test treatments

May 7, 2015
A study, published today in Cell, demonstrates the power of organoids to capture, in three dimensions, the multiple mutations that occur in tumours. Organoids, small clusters of cells that accurately mimic the behaviour of ...

Genetic mutations found linked to rare cases of multiple bowel tumors

July 5, 2016
Researchers have identified genetic mutations affecting the immune system which may lead to the development of more than one bowel tumour at the same time. Understanding how these cancers develop could improve targeting of ...

Genetic signatures expose drug susceptibility in breast cancer cells

June 25, 2016
Drug treatments for breast cancer patients might soon be designed based on the unique genetic autograph of their tumor.

Genetic signatures of gastric cancer cell lines reveal disease subtypes

April 30, 2015
Distinct subtypes of gastric cancer respond differently to drug treatments according to a study by A*STAR researchers. The finding could help optimize treatment for individuals with gastric cancer and improve their prognosis.

Various miRNAs predict the effect of anti-angiogenic agents on renal cancer

July 7, 2016
A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group (SOGUG) and the University Hospitals Leuven (Belgium), has discovered various potential biomarkers predictive of tyrosine kinase inhibitors ...

Blood test supports use of potential new treatment for patients with stomach cancer

May 27, 2016
Testing cancers for 'addiction' to a gene that boosts cell growth can pick out patients who may respond to a targeted drug under development, a major new study reports.

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Inflammatory bowel disease linked to prostate cancer

December 7, 2018
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.